Form 4: DiaMedica Therapeutics Director James T. Parsons Acquires Shares and Stock Options
SEC Form 4 Filing
Director James T. Parsons reports acquisition of DiaMedica Therapeutics shares and stock options.
Summary
- On June 1, 2024, James T. Parsons, a director of DiaMedica Therapeutics Inc., reported a transaction involving the company's securities.
- Parsons acquired 28,472 stock options with an exercise price of $2.90, vesting in quarterly installments over one year and expiring on May 31, 2034.
- Parsons directly owns 59,937 voting common shares, including shares issuable upon settlement of deferred share units.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard disclosure of insider transactions. The acquisition of shares and options could be seen as a positive signal, but it's not definitive.
Positives
- The acquisition of stock options by a director may indicate confidence in the company's future performance.
Industry Context
Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the transactions of company insiders.
Stakeholder Impact
- The transaction could have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 06/01/2024 | Date of earliest transaction: Acquisition of stock options. |
| 06/03/2024 | Date of signature on the Form 4 filing. |
| 05/31/2034 | Expiration date of the acquired stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.